Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
about
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancerChanges in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancerNatural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV propertiesA novel mechanism of plasmin-induced mitogenesis in fibroblasts.Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts.Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain.PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor.Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism.Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle.Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.Steps in prostate cancer progression that lead to bone metastasisNatural and engineered plasmin inhibitors: applications and design strategies.The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases.Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells.213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal modelChallenges for drug discovery - a case study of urokinase receptor inhibitionThe superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies.Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report.A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
P2860
Q24619151-9AA3BA25-0695-482B-8F7D-3998FE0F8B55Q24807354-6C0040B0-F5D6-4387-9191-06825ABDEA13Q28344956-283A345C-9314-4FEF-8F19-EF2352F635C6Q33693462-4D3FE21B-00C0-410C-9D8A-510DB2AB2480Q34075406-6531908C-BDCF-42CA-8D62-3598419B77D5Q34467715-601F567B-9D9C-44FD-9547-CDD7E36B0E21Q34475106-EB9C4B64-F48E-4579-8E4E-1BFE1E2A7DA2Q35079577-786A4CE6-A173-4C19-9078-5C7349857272Q36143607-A674E94C-FB27-45E6-971E-6404EBACC3D2Q36259662-058D8F80-5ADC-4B10-9164-E801750F9179Q36614744-DAA809AA-15D7-40AD-A075-9DA6A3E98FB0Q36640228-1D1BD6C1-0E8B-4729-90B9-6C07977A8501Q37695659-95DFA1E8-2ED4-428C-84B1-A6EEA1186EC8Q37848782-1F03B641-854F-4CA4-AC60-21A33844EF2DQ37975189-E4FDD042-922D-4BA2-A6DA-27D86C474D69Q39640346-AF85E73D-DC59-4AC4-8913-8D4E58028F14Q39706283-E5CEF2E5-6D3C-4BF2-9F1F-EE5DD2E92978Q40646743-A3B609A8-A83F-47B5-9031-D9A66589B0F1Q40738194-88E4BD69-E60F-4FD0-BF78-5E1409B43CBDQ41908264-ED4E5919-68F8-431D-B42A-98AD9B978708Q42029795-3E9A0196-7A8D-4E90-B6EB-6E05F3CE5DE7Q42084404-05DFC9EC-E28D-4D66-B1CF-0CEAD7167FE6Q42387360-DAFF1A57-7D9F-4DB8-BE3F-76120D92E391Q42855032-EBEA76BD-7219-4C60-9779-80009957191BQ46906937-DAE16323-A042-42D6-8073-D789E3428D2BQ48452045-4E3B6922-912D-48D8-9E0B-D633D7228D39
P2860
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Plasminogen activator system m ...... tion in prostatic tumor cells.
@en
type
label
Plasminogen activator system m ...... tion in prostatic tumor cells.
@en
prefLabel
Plasminogen activator system m ...... tion in prostatic tumor cells.
@en
P2093
P356
P1476
Plasminogen activator system m ...... tion in prostatic tumor cells.
@en
P2093
P2888
P304
P356
10.1023/A:1006590217724
P577
1998-08-01T00:00:00Z
P6179
1049016846